NAYA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAYA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
NAYA Biosciences's Book Value per Share for the quarter that ended in Sep. 2024 was $-1.96.
During the past 12 months, NAYA Biosciences's average Book Value per Share Growth Rate was -1400.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of NAYA Biosciences was 52.70% per year. The lowest was -47.70% per year. And the median was 10.35% per year.
For the Medical Devices subindustry, NAYA Biosciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, NAYA Biosciences's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where NAYA Biosciences's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
NAYA Biosciences (NAS:NAYA) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Thank you for viewing the detailed overview of NAYA Biosciences's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Trent D Davis | director | 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204 |
Matthew K Szot | director | 802 NORTH DOUTY STREET, HANFORD CA 93230 |
Steve Shum | director | 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070 |
Andrea Goren | officer: Chief Financial Officer | 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022 |
Barbara Ryan | director | 22 CAVRAY ROAD, NORWALK CT 06855 |
Michael Jos. Campbell | director | 61 SOUTH HILLS DRIVE, BEDFORD NH 03110 |
Rebecca Messina | director | 5582 BROADCAST COURT, SARASOTA FL 34240 |
Jeffrey Segal | director | INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240 |
Awm Investment Company, Inc. | 10 percent owner | 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022 |
Kevin Doody | director, officer: Medical Director | 1109 SOMERSET BLVD, COLLEYVILLE TX 76034 |
Debra Robbins Hoopes | officer: Acting CFO and PFO | 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903 |
Claude Ranoux | 10 percent owner | 8 CHESTNUT STREET, WINCHESTER MA 01890 |
Kathleen T Karloff | director, officer: CEO/Chairman | 109 BEACON STREET UNIT 5, BOSTON MA 02116 |
Bowdring Robert Joseph Jr | officer: Chief Financial Officer | 92 GOULD STREET, WAKEFIELD MA 01880 |
From GuruFocus
By PRNewswire • 10-23-2023
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 05-15-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 10-21-2024
By PRNewswire • 11-28-2023
By Marketwired • 10-24-2023
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.